Paroxetine (Paxil) is an SSRI antidepressant with one of the broadest FDA-approved profiles, covering major depression, generalized anxiety, panic disorder, social anxiety, OCD, PTSD, and PMDD. It works by blocking the serotonin transporter (SERT), with additional anticholinergic and norepinephrine reuptake inhibitory activity. Common side effects — more pronounced than other SSRIs — include sexual dysfunction, weight gain, sedation, sweating, and dry mouth. It is a potent CYP2D6 inhibitor that substantially raises levels of co-administered drugs like TCAs and metoprolol; its short half-life produces the most severe discontinuation syndrome of any SSRI, and it is the only SSRI classified as Pregnancy Category D due to first-trimester cardiac malformation risk.
Paroxetine
Uses & FDA Indications
Paroxetine holds one of the broadest FDA-approved indication profiles among all SSRIs, spanning multiple psychiatric conditions across the anxiety and mood disorder spectrum. This breadth, combined with decades of post-marketing data, makes it a frequently prescribed agent — though its side effect profile and interaction potential have increasingly led prescribers toward newer SSRIs for first-line use in many patients.
FDA-approved indications include: major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder (with or without agoraphobia), social anxiety disorder (social phobia), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). A low-dose formulation (Brisdelle) is specifically approved for vasomotor symptoms (hot flashes) associated with menopause — a non-psychiatric indication that exploits serotonergic modulation of thermoregulatory pathways.
Off-label uses include premature ejaculation (where its sexual side effects are exploited therapeutically), hot flashes in breast cancer survivors who cannot take hormonal therapy, and certain chronic pain syndromes. Notably, paroxetine is generally avoided in breast cancer patients taking tamoxifen due to CYP2D6-mediated interference with tamoxifen activation.
How It Works
Paroxetine selectively inhibits the serotonin transporter (SERT), blocking presynaptic reuptake of serotonin from the synapse. This increases serotonergic neurotransmission in brain regions implicated in mood and anxiety regulation, including the prefrontal cortex, amygdala, and limbic system. Full therapeutic response typically requires several weeks because downstream receptor adaptations — including desensitization of inhibitory somatodendritic 5-HT1A autoreceptors — are necessary for the net increase in serotonergic tone.
Beyond SERT inhibition, paroxetine has meaningful pharmacological activity at other receptor systems that distinguishes it from "cleaner" SSRIs like escitalopram. It has notable muscarinic (anticholinergic) activity, which contributes to dry mouth, constipation, urinary hesitancy, and cognitive effects. It also has moderate norepinephrine reuptake inhibition and sigma-1 receptor binding. These additional activities account for both its broader symptom coverage and its more complex side effect profile compared to other SSRIs.
Paroxetine is among the most potent inhibitors of CYP2D6 of any antidepressant. Because CYP2D6 metabolizes paroxetine itself, the drug inhibits its own metabolism — a phenomenon called autoinhibition. This means that with dose escalation, drug levels increase disproportionately (nonlinear pharmacokinetics), and drug-drug interactions become amplified at higher doses.
BLACK BOX WARNING: Antidepressants increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (under age 25) in short-term studies. Paroxetine is not approved for use in pediatric patients. Monitor all patients closely for clinical worsening and emergence of suicidal ideation, especially during the first few months of treatment and after dose changes.
Side Effects
Common
- Sexual dysfunction — one of the most common and treatment-limiting effects: decreased libido, delayed ejaculation, anorgasmia, and erectile dysfunction. Rates are higher with paroxetine than with most other SSRIs.
- Weight gain — more pronounced than with most SSRIs; particularly notable with long-term use.
- Nausea — most common early in treatment; typically resolves within 1–2 weeks. Taking with food reduces severity.
- Sedation and fatigue — more common than with activating SSRIs; related partly to anticholinergic and histamine activity.
- Dry mouth, constipation — anticholinergic effects; more prominent than with other SSRIs.
- Sweating — night sweats and excessive diaphoresis are common; particularly notable with paroxetine.
- Tremor, headache, dizziness
Serious
- Discontinuation syndrome — paroxetine produces the most severe and frequent discontinuation syndrome among SSRIs, characterized by "brain zaps," dizziness, flu-like symptoms, irritability, and rebound anxiety. Abrupt cessation must be avoided.
- Serotonin syndrome — potentially life-threatening when combined with other serotonergic agents. Presents with agitation, hyperthermia, tachycardia, diaphoresis, and neuromuscular abnormalities including clonus and hyperreflexia.
- Hyponatremia — SIADH-related low sodium, particularly in elderly patients. Can cause confusion, seizures, and death if severe.
- Bleeding risk — SSRIs reduce platelet serotonin and impair platelet aggregation, increasing bleeding risk, particularly GI bleeding when combined with NSAIDs or anticoagulants.
- Teratogenicity — paroxetine carries a Pregnancy Category D designation; associated with increased risk of cardiac malformations when used in the first trimester. Neonatal SSRI discontinuation syndrome can occur with late-pregnancy use.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAOIs (phenelzine, tranylcypromine, selegiline, linezolid) | Severe serotonin syndrome risk — potentially fatal. Both agents increase serotonergic transmission by different mechanisms. Linezolid, an antibiotic with MAOI-like activity, carries the same contraindication. | Contraindicated — 14-day washout after MAOI; 14-day washout after paroxetine before starting MAOI |
| Tamoxifen | Paroxetine inhibits CYP2D6-mediated conversion of tamoxifen to its active metabolite endoxifen, substantially reducing plasma endoxifen levels and potentially compromising breast cancer treatment efficacy. | High — generally contraindicated in patients taking tamoxifen; choose an SSRI with minimal CYP2D6 inhibition (citalopram, escitalopram, venlafaxine) |
| Tricyclic Antidepressants (amitriptyline, nortriptyline, desipramine) | CYP2D6 inhibition by paroxetine markedly increases TCA plasma levels, raising risk of cardiotoxicity (QT prolongation, arrhythmia) and anticholinergic toxicity. | High — avoid combination; if necessary, use very low TCA doses with plasma level monitoring and ECG |
| Codeine and Tramadol | Both are prodrugs requiring CYP2D6 activation. Paroxetine blocks their conversion to active opioid metabolites, reducing analgesia. Tramadol also has serotonergic activity, adding serotonin syndrome risk. | High — codeine becomes ineffective; tramadol carries dual risk. Consider alternative analgesics. |
| Antipsychotics (haloperidol, risperidone, aripiprazole, perphenazine) | CYP2D6 inhibition raises antipsychotic plasma levels, increasing EPS risk and other adverse effects. Aripiprazole and risperidone levels can increase substantially. | Moderate-High — monitor for adverse effects; dose reduction of the antipsychotic is often required |
| Metoprolol and CYP2D6-metabolized beta-blockers | Paroxetine inhibits metoprolol metabolism, raising plasma levels 3–5 fold. May cause symptomatic bradycardia and heart block. | Moderate — monitor heart rate; consider atenolol (not CYP2D6-dependent) as an alternative |
| NSAIDs and Anticoagulants (warfarin, aspirin, ibuprofen) | Additive bleeding risk due to SSRI-mediated platelet dysfunction plus antiplatelet or anticoagulant action. GI bleeding risk is substantially elevated with concurrent NSAID use. | Moderate — consider gastroprotection with a PPI; monitor INR if used with warfarin |
| Other Serotonergic Agents (triptans, fentanyl, St. John's Wort, lithium) | Additive serotonergic activity increases serotonin syndrome risk to varying degrees by agent. | Moderate — use with caution; monitor for serotonin syndrome signs |
Warnings & Contraindications
Contraindications
- Concurrent use with MAOIs (or within 14 days of MAOI discontinuation)
- Concurrent use with thioridazine or pimozide (serious QT prolongation risk via CYP2D6 inhibition)
- Hypersensitivity to paroxetine
- Concurrent tamoxifen therapy for breast cancer (relative contraindication based on efficacy data)
Pregnancy — Category D
Paroxetine is the only SSRI to carry an FDA Pregnancy Category D designation. Epidemiological studies have found an increased risk of congenital cardiovascular malformations, particularly ventricular septal defects, with first-trimester exposure. Neonates exposed to SSRIs late in pregnancy may experience a neonatal adaptation syndrome — respiratory distress, irritability, and feeding difficulties — requiring NICU monitoring. In women of childbearing age, the risks and benefits should be carefully weighed and alternative SSRIs considered for new prescriptions.
Discontinuation — Taper Slowly
Paroxetine must not be stopped abruptly. Its short half-life (roughly 21 hours, compared to fluoxetine's 4–6 days) means serotonin levels drop sharply with each missed dose. Discontinuation syndrome symptoms — brain zaps, dizziness, nausea, irritability, rebound anxiety, flu-like malaise — can begin within 24–48 hours of stopping. A systematic taper over weeks to months with small incremental dose reductions is the standard approach. Patients who are particularly sensitive may require a switch to fluoxetine (which self-tapers due to its long half-life) before discontinuing entirely.
Suicidality and Monitoring
Like all antidepressants, paroxetine carries an FDA black box warning regarding increased risk of suicidal ideation in patients under 25 years during the early treatment period. Clinical monitoring — especially in the first 4 weeks and after any dose change — is recommended. Paroxetine is not approved for pediatric psychiatric indications.
Check for serotonin syndrome risk or CYP2D6 interactions with paroxetine.
Check Drug Interactions →Frequently Asked Questions
Why is paroxetine so hard to stop taking?
Paroxetine has the most pronounced discontinuation syndrome among all SSRIs, primarily due to its short half-life (approximately 21 hours) and potent serotonin reuptake inhibition. When stopped abruptly, serotonin signaling drops rapidly, producing electric shock sensations ("brain zaps"), dizziness, flu-like symptoms, irritability, anxiety, and vivid dreams. These symptoms are not withdrawal in the addiction sense — they do not indicate dependence — but they can be severely uncomfortable. Slow, gradual tapering over weeks to months substantially reduces their severity.
Does paroxetine cause weight gain?
Yes — paroxetine is associated with more weight gain than most other SSRIs, particularly with long-term use. Studies suggest average weight gain of 2–5 kg over 6–12 months, though individual variation is wide. The mechanism likely involves serotonin receptor effects on appetite regulation, anticholinergic properties that may affect metabolism, and increased appetite as mood improves. Patients who are weight-conscious or have obesity-related comorbidities may be better served by SSRIs with more neutral weight profiles such as sertraline or escitalopram.
Can paroxetine affect other medications I take?
Yes, significantly. Paroxetine is one of the most potent inhibitors of the CYP2D6 liver enzyme among all antidepressants. It can substantially raise blood levels of other drugs metabolized by CYP2D6 — including tricyclic antidepressants, antipsychotics (haloperidol, risperidone), opioids (codeine, tramadol), beta-blockers (metoprolol), and the breast cancer drug tamoxifen. For tamoxifen in particular, paroxetine is generally contraindicated because it blocks the conversion of tamoxifen to its active metabolite endoxifen, potentially reducing cancer treatment efficacy.